📊 BFNH Key Takeaways
Investment Thesis
BFNH exhibits severe financial distress with negative stockholders' equity of -$499.9K, indicating the company is technically insolvent. The company generated only $17.8K in revenue against $1.2M in net losses, demonstrating a fundamentally broken business model with no viable path to profitability. Negative operating cash flow and zero insider confidence complete a picture of a company in existential crisis.
BFNH Strengths
- Minimal cash burn relative to asset base in current period
- Positive gross margin of 24.5% indicates some pricing power on limited sales
- Laboratory analytical instruments sector has legitimate long-term demand
BFNH Risks
- Negative stockholders' equity of -$499.9K represents technical insolvency
- Revenue of only $17.8K annually is insufficient to support operations or debt service
- Operating losses of -$372.2K with net losses of -$1.2M indicate business model failure
- Negative operating cash flow of -$54.2K shows cash burn despite minimal operations
- Current ratio of 0.00x indicates severe liquidity crisis with inability to meet obligations
- No insider activity in 90 days suggests management disengagement
- Extreme negative margins (-2093.7% operating, -6601.1% net) demonstrate complete operational failure
Key Metrics to Watch
- Whether company remains operating or files for bankruptcy
- Any revenue recovery toward minimum viable operating levels
- Stockholders' equity trend and whether insolvency worsens
BFNH Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BFNH Profitability Ratios
BFNH vs Default Sector
How BIOFORCE NANOSCIENCES HOLDINGS, INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BFNH Balance Sheet & Liquidity
BFNH 5-Year Financial Trend
5-Year Trend Summary: BIOFORCE NANOSCIENCES HOLDINGS, INC.'s revenue has shown modest growth of 9% over the 5-year period. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
BFNH Growth Metrics (YoY)
BFNH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $6.0K | -$6.3K | N/A |
| Q2 2020 | $6.0K | -$7.2K | N/A |
| Q1 2020 | $5.9K | -$12.9K | N/A |
| Q3 2019 | $5.5K | -$6.3K | N/A |
| Q2 2019 | $5.1K | -$7.2K | N/A |
| Q1 2019 | $5.9K | -$12.9K | N/A |
| Q3 2018 | $5.5K | -$2.2K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BFNH Capital Allocation
BFNH SEC Filings
Access official SEC EDGAR filings for BIOFORCE NANOSCIENCES HOLDINGS, INC. (CIK: 0001310488)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BFNH
What is the AI rating for BFNH?
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BFNH's key strengths?
Minimal cash burn relative to asset base in current period. Positive gross margin of 24.5% indicates some pricing power on limited sales.
What are the risks of investing in BFNH?
Negative stockholders' equity of -$499.9K represents technical insolvency. Revenue of only $17.8K annually is insufficient to support operations or debt service.
What is BFNH's revenue and growth?
BIOFORCE NANOSCIENCES HOLDINGS, INC. reported revenue of $17.8K.
Does BFNH pay dividends?
BIOFORCE NANOSCIENCES HOLDINGS, INC. does not currently pay dividends.
Where can I find BFNH SEC filings?
Official SEC filings for BIOFORCE NANOSCIENCES HOLDINGS, INC. (CIK: 0001310488) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BFNH's EPS?
BIOFORCE NANOSCIENCES HOLDINGS, INC. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.